Alginate/Poly-L-Lysine Microparticles for the Intestinal Delivery of Antisense Oligonucleotides
- 235 Downloads
Purpose. A microparticle carrier based on alginate and poly-L-lysine was developed and evaluated for the delivery of antisense oligonucleotides at the intestinal site. Formulations of oligonucleotide-loaded microparticles having differences in the carrier molecular weight and composition were characterized in vitro and in vivo.
Methods. Polymeric microparticles were prepared by ionotropic gelation and crosslinking of alginate with calcium ions and poly-L-lysine. The loading of the antisense oligonucleotide into the microparticles was achieved by absorption in aqueous medium. The association capacity, loading and particle size of the microparticles were characterized. The in vivo performances of various formulations after intrajejunal administration were studied in rat and in dog models.
Results. Microparticles had a sponge-like structure and an oligonucleotide loading of 27-35%. The composition of the medium affected the particle size and the in vitro release profiles. The oligonucleotide bioavailability after intrajejunal administration to rats in the presence of permeation enhancers was good for most of the tested systems. The application of microparticles in powder form compared to an equivalent suspension improved the intrajejunal bioavailability of the oligonucleotide (25% and 10% respectively) in rats. On the contrary, the intrajejunal administration to dogs resulted in poor oligonucleotide bioavailability (0.42%).
Conclusions. The formulation of antisense oligonucleotides within alginate and poly-L-lysine microparticles is a promising strategy for the oral application.
Unable to display preview. Download preview PDF.
- 1.P. D. Cook. Antisense medicinal chemistry. In S.T. Crooke (eds), Antisense Research and Application; Handbook of Experimental Pharmacology, Vol. 131, Springer-Verlag, Berlin, 1998, pp. 51–101.Google Scholar
- 2.R. M. Crooke. Cellular uptake, distribution and metabolism of phosphorothioate, phosphodiester, and methylphosphonate oligonucleotides. In S.T. Crooke and B. Lebleu (eds), Antisense Research and Applications, CRC Press, Florida, 1993, pp. 427–449.Google Scholar
- 3.G. Stix. Shutting down a gene. Antisense drug wins approval. Sci. Am. 279:46–50 (1998).Google Scholar
- 4.I. Lebedeva, L. Benimetskaya, C. A. Stein, and M. Vilenchik. Cellular delivery of antisense oligonucleotides. Eur. J. Pharm. Biopharm. 50:101–119 (2000).Google Scholar
- 5.R. S. Geary, J. M. Leeds, S. P. Henry, D. K. Monteith, and A. A. Levin. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anti-Cancer Drug Design 12:383–393 (1997).Google Scholar
- 6.P. L. Nicklin, S. J. Craig, and J. A. Phillips. Pharmacokinetic properties of phosphorothioates in animals, absorption, distribution, metabolism and elimination. In S.T. Crooke (ed). Antisense Research and Application; Handbook of Experimental Pharmacology, Vol. 131, Springer-Verlag, Berlin, 1998. pp. 141–168.Google Scholar
- 7.E. Wagner. Application of membrane-active peptides for nonviral gene delivery. Adv. Drug Deliv. Rev. 38:279–289 (1999).Google Scholar
- 8.S. Akhtar, M. D. Hughes, A. Khan, M. Bibby, M. Hussain, Q. Nawaz, J. Double, and P. Sayyed. The delivery of antisense therapeutics. Adv. Drug Deliv. Rev. 44:3–21 (2000).Google Scholar
- 9.F. Lim and A. M. Sun. Microencapsulated islets as bioartificial endocrine pancreas. Science 210:908–910 (1980).Google Scholar
- 10.R. P. Lanza, R. Jackson, A. Sullivan, J. Ringeling, C. McGrath, W. Kuhtreiber, and W. L. Chick. Xenotransplantation of cells using biodegradable microcapsules. Transplantation 67:1105–1111 (1999).Google Scholar
- 11.D. Lemoine, F. Wauters, S. Bouchendhomme, and V. Préat. Preparation and characterization of alginate microspheres containing a model antigen. Int. J. Pharm. 176:9–19 (1998).Google Scholar
- 12.T. L. Bowersock. H. HogenEsch, M. Suckow, P. Guimond, S. Martin, D. Borie, S. Torregrosa, H. Park and K. Park. Oral vaccination of animals with antigens encapsulated in alginate microspheres. Vaccine 17:1804–1811 (1999).Google Scholar
- 13.I. Aynie, C. Vauthier, H. Chacun, E. Fattal, and P. Couvreur. Spongelike alginate nanoparticles as a new potential system for the delivery of antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 9:301–312 (1999).Google Scholar
- 14.B. Thu, P. Bruheim, T. Espevik, O. Smidsrød, P. Soon-Shiong, and G. Skjåk-Bræk. Alginate polycation microcapsules: I. Interaction between alginate and polycation. Biomaterials 17:1031–1040 (1996).Google Scholar
- 15.H. E. Junginger. Mucoadhesive hydrogels. Pharm. Ind. 53:1056–1065 (1991).Google Scholar
- 16.W. R. Gombotz and S. F. Wee. Protein release from alginate matrices. Adv. Drug Deliv. Rev. 31:267–285 (1998).Google Scholar
- 17.A. V. Kabanov. Taking polycation gene delivery systems from in vitro to in vivo. PSTT 2:365–372 (1999).Google Scholar
- 18.S. C. De Smedt, J. Demeester, and W. E. Hennink. Cationic polymer based gene delivery systems. Pharm. Res. 17:113–126 (2000).Google Scholar
- 19.V. H. L. Lee, A. Yamamoto, and U. Bhaskar Kompella. Mucosal penetration enhancers for facilitation of peptide and protein drug absorption. Crit. Rev. Ther. Drug Carrier Syst. 8:91–192 (1991).Google Scholar
- 20.T. Lindmark, Y. Kimura, and P. Artursson. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells. J. Pharmacol. Exp. Ther. 284:362–369 (1998).Google Scholar
- 21.L. A. Lapierre. The molecular structure of the tight junction. Adv. Drug Deliv. Rev. 41:255–264 (2000).Google Scholar
- 22.A. Fasano. Novel approaches for oral delivery of macromolecules. J. Pharm. Sci. 87:1351–1356 (1998).Google Scholar
- 23.D. J. Brayden. and D. J. O. Mahony. Novel oral drug delivery gateways for biotechnology products: polypeptides and vaccines. PSTT 1:291–299 (1998).Google Scholar
- 24.C. F. Bennett, J. E. Zuckerman, D. Kornbrust, H. Sasmor, J. M. Leeds, and S. T. Crooke. Pharmacokinetics in mice of a [3H]-labeled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid. J. Cont. Release 41:121–130 (1996).Google Scholar
- 25.M. Rajaonarivony, C. Vauthier, G. Couarraze, F. Puisieux, and P. Couvreur. Development of a new drug carrier made from alginate. J. Pharm. Sci. 82:912–917 (1993).Google Scholar
- 26.M. Butler, K. Stecker, and C. F. Bennett. Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab. Invest. 77:379–388 (1997).Google Scholar
- 27.M. Butler, K. Stecker, and C. F. Bennett. Histologic localization of phosphorothioate oligodeoxynucleotides in normal rodent tissue. Nucleosides & Nucleotides 16:1761–1764 (1997).Google Scholar